Login to Your Account



Taiwan, China biopharmas to develop HCV treatment in 1st cross-straits deal

By Pearl Liu
Staff Writer

Friday, November 11, 2016

SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic HCV.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription